Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia.
Saved in:
| Title: | Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia. |
|---|---|
| Authors: | Eid N; Pediatric Hematology/Oncology Fellowship Program, Children's Hospital of Michigan, Detroit, Michigan., Zhao J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Thibodeau J; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan., Edwards H; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Li J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Bao X; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Polin L; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Kushner J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Dzinic SH; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., White K; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Buck SA; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan., Back JB; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan., Stemmer PM; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan., Lee M; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan., Kim S; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Taub JW; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan.; Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan., Ge Y; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan. |
| Source: | ASPET discovery [ASPET Discov] 2025; Vol. 1. Date of Electronic Publication: 2025 Sep 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918994891106676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 3050-5674 (Electronic) Linking ISSN: 30505674 NLM ISO Abbreviation: ASPET Discov Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42422326 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Eid+N%22">Eid N</searchLink>; Pediatric Hematology/Oncology Fellowship Program, Children's Hospital of Michigan, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Zhao+J%22">Zhao J</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Thibodeau+J%22">Thibodeau J</searchLink>; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Edwards+H%22">Edwards H</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Bao+X%22">Bao X</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Polin+L%22">Polin L</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Kushner+J%22">Kushner J</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Dzinic+SH%22">Dzinic SH</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22White+K%22">White K</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Buck+SA%22">Buck SA</searchLink>; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Back+JB%22">Back JB</searchLink>; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Stemmer+PM%22">Stemmer PM</searchLink>; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Lee+M%22">Lee M</searchLink>; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Taub+JW%22">Taub JW</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan.; Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Ge+Y%22">Ge Y</searchLink>; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918994891106676%22">ASPET discovery</searchLink> [ASPET Discov] 2025; Vol. 1. <i>Date of Electronic Publication: </i>2025 Sep 25. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918994891106676 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>3050-5674 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2230505674%22">30505674 </searchLink><i>NLM ISO Abbreviation: </i>ASPET Discov <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42422326 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.aspetd.2025.100014 Languages: – Code: eng Text: English Titles: – TitleFull: Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Eid N – PersonEntity: Name: NameFull: Zhao J – PersonEntity: Name: NameFull: Thibodeau J – PersonEntity: Name: NameFull: Edwards H – PersonEntity: Name: NameFull: Li J – PersonEntity: Name: NameFull: Bao X – PersonEntity: Name: NameFull: Polin L – PersonEntity: Name: NameFull: Kushner J – PersonEntity: Name: NameFull: Dzinic SH – PersonEntity: Name: NameFull: White K – PersonEntity: Name: NameFull: Buck SA – PersonEntity: Name: NameFull: Back JB – PersonEntity: Name: NameFull: Stemmer PM – PersonEntity: Name: NameFull: Lee M – PersonEntity: Name: NameFull: Kim S – PersonEntity: Name: NameFull: Taub JW – PersonEntity: Name: NameFull: Ge Y IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 3050-5674 Numbering: – Type: volume Value: 1 Titles: – TitleFull: ASPET discovery Type: main |
| ResultId | 1 |
